LDN 193189 hydrochloride manufacturers
- LDN-193189 2HCl
-
- $67.00 / 5mg
-
2026-04-22
- CAS:1435934-00-1
- Min. Order:
- Purity: 99.87%
- Supply Ability: 10g
|
| | LDN 193189 hydrochloride Basic information |
| Product Name: | LDN 193189 hydrochloride | | Synonyms: | LDN-193189 2HCl;LDN 193189 dihydrochloride;4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride;Viomycin LDN 193189 Dihydrochloride;DM-3189 2HCl;LDN-193189 2HC;LDN-193189 (DM3189) 2HCl;LDN-193189 2HCl|||DM-3189 2HCl | | CAS: | 1435934-00-1 | | MF: | C25H24Cl2N6 | | MW: | 479.40426 | | EINECS: | | | Product Categories: | | | Mol File: | 1435934-00-1.mol |  |
| | LDN 193189 hydrochloride Chemical Properties |
| storage temp. | -20°C | | solubility | Soluble in DMSO or in Water (up to 5 mg/ml) | | form | solid | | color | Orange-yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 2 months. |
| | LDN 193189 hydrochloride Usage And Synthesis |
| Description | LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM. In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively). LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone. | | Uses | LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3]. | | in vivo | LDN-193189 (i.p.; 3 mg/kg; daily; for 35 days) might affect the interaction between breast cancer cells and the bone environment[3].
LDN-193189 (i.p.; 3 mg/kg; single) shows a reduction in ectopic ossification and functional impairment[1]. | | storage | -20°C | | References | [1] BMP type 1 receptor inhibition reduces heterotropic ossification
[2] STUART M CHAMBERS. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors[J]. Nature biotechnology, 2012, 30 7: 715-720. DOI:10.1038/nbt.2249
[3] FAITH R KREITZER. A robust method to derive functional neural crest cells from human pluripotent stem cells.[J]. American journal of stem cells, 2013, 2 2: 119-131.
[4] YU-CHEN LEE. BMP4 promotes prostate tumor growth in bone through osteogenesis.[J]. Cancer research, 2011: 5194-5203. DOI:10.1158/0008-5472.can-10-4374 |
| | LDN 193189 hydrochloride Preparation Products And Raw materials |
|